The European Commission imposed fines on pharmaceutical ingredient manufacturer Alchem following an investigation that uncovered cartel activities spanning over ten years. The probe centered on anti-competitive practices involving active pharmaceutical ingredients (APIs). This enforcement action demonstrates regulatory scrutiny in the pharmaceutical supply chain aimed at maintaining market fairness and integrity.